Pfizer's Xeljanz Cuts Incidence Of Death, Respiratory Failure In COVID-19 Patients, Brazilian Study Shows

·1 min read
  • Pfizer Inc (NYSE: PFE) said that its oral rheumatoid arthritis drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s primary goal.

  • Results of the study, which tested the drug in 289 hospitalized adult patients with respiratory illness due to the infection, were published in the New England Journal of Medicine.

  • Incidence of death or respiratory failure was 18.1% for patients treated with the drug compared to 29% for placebo.

  • Death from any cause through day 28 occurred in 2.8% of patients in the tofacitinib group and 5.5% in the placebo group.

  • Serious adverse events occurred in 20 patients treated with the drug compared to 17 patients on placebo.

  • The incidence of severe infection was 3.5% in the tofacitinib group and 4.2% in the placebo group.

  • Xeljanz belongs to a class of drugs called JAK inhibitors and is approved in four indications.

  • Price Action: PFE shares are down 0.05% at $39.28 during the premarket trading session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting